Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Given Average Recommendation of “Moderate Buy” by Brokerages

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $8.00.

A number of equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Bank of America reduced their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. JMP Securities reduced their price target on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Finally, Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research report on Monday, August 25th.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Quadrature Capital Ltd purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at approximately $28,000. Vontobel Holding Ltd. purchased a new position in Werewolf Therapeutics in the first quarter valued at $34,000. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics in the second quarter valued at $48,000. Nuveen LLC purchased a new position in Werewolf Therapeutics in the first quarter valued at $71,000. Finally, AQR Capital Management LLC purchased a new position in Werewolf Therapeutics in the first quarter valued at $79,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Werewolf Therapeutics Trading Up 2.5%

Werewolf Therapeutics stock opened at $1.67 on Wednesday. The stock has a 50-day moving average of $1.53 and a two-hundred day moving average of $1.24. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.30 and a current ratio of 5.30. Werewolf Therapeutics has a one year low of $0.60 and a one year high of $4.18. The stock has a market cap of $76.37 million, a PE ratio of -1.02 and a beta of 0.76.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. On average, research analysts anticipate that Werewolf Therapeutics will post -1.56 EPS for the current fiscal year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.